Theriva Biologics, Inc.

Analysis for Ticker: TOVX

Theriva Biologics Inc is a clinical-stage company developing virus treatments for cancer and gut health. Behind the science is an accumulated deficit of 358,7$ million. This is a machine that consumes capital to pay for its own failure. Think of it like a pizza that keeps getting sliced into smaller and smaller pieces; the company keeps printing new shares to sell for cash, which means the piece you own shrinks every single day. The math is a disaster because they have zero product revenue and incinerated 16,7$ million in operating cash in 2025 alone.